1. Home
  2. MPT vs SRPT Comparison

MPT vs SRPT Comparison

Compare MPT & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medical Properties Trust Inc. common stock

MPT

Medical Properties Trust Inc. common stock

N/A

Current Price

$3.92

Market Cap

2.4B

Sector

Real Estate

ML Signal

N/A

Logo Sarepta Therapeutics Inc. (DE)

SRPT

Sarepta Therapeutics Inc. (DE)

HOLD

Current Price

$22.14

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPT
SRPT
Founded
2003
1980
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.0B
IPO Year
2004
2000

Fundamental Metrics

Financial Performance
Metric
MPT
SRPT
Price
$3.92
$22.14
Analyst Decision
Hold
Hold
Analyst Count
1
29
Target Price
$5.00
$25.85
AVG Volume (30 Days)
7.8M
2.9M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
6.43%
N/A
EPS Growth
88.56
N/A
EPS
0.05
2.99
Revenue
$972,022,000.00
$2,198,237,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$4.91
N/A
P/E Ratio
$79.80
$7.00
Revenue Growth
N/A
15.58
52 Week Low
$3.89
$14.68
52 Week High
$6.47
$25.32

Technical Indicators

Market Signals
Indicator
MPT
SRPT
Relative Strength Index (RSI) 34.30 61.76
Support Level N/A $20.12
Resistance Level $5.32 $23.71
Average True Range (ATR) 0.11 1.53
MACD 0.01 0.16
Stochastic Oscillator 20.31 73.51

Price Performance

Historical Comparison
MPT
SRPT

About MPT Medical Properties Trust Inc. common stock

Medical Properties Trust Inc acquires and develops net-leased healthcare facilities. Its investments in healthcare real estate, other loans, and any investments in tenants are considered a single reportable segment. Its business strategy is to acquire and develop healthcare facilities and lease the facilities to healthcare operating companies under long-term net leases, which require the tenant to bear of the costs associated with the property. The group's geographic areas are the United States, the United Kingdom, and All other countries.

About SRPT Sarepta Therapeutics Inc. (DE)

Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.

Share on Social Networks: